295 related articles for article (PubMed ID: 36037651)
21. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
22. Huaier improves the efficacy of anti-PD-L1 Ab in the treatment of hepatocellular carcinoma by regulating tumor immune microenvironment.
Li H; You J; Wei Y; Zheng L; Yang J; Xu J; Li Y; Li Z; Yang X; Yi C
Phytomedicine; 2024 Jan; 123():155189. PubMed ID: 37984124
[TBL] [Abstract][Full Text] [Related]
23. Interferon-α Up-Regulates the Expression of PD-L1 Molecules on Immune Cells Through STAT3 and p38 Signaling.
Bazhin AV; von Ahn K; Fritz J; Werner J; Karakhanova S
Front Immunol; 2018; 9():2129. PubMed ID: 30356906
[TBL] [Abstract][Full Text] [Related]
24. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.
Macek Jilkova Z; Aspord C; Kurma K; Granon A; Sengel C; Sturm N; Marche PN; Decaens T
Clin Transl Gastroenterol; 2019 Jul; 10(7):e00058. PubMed ID: 31295151
[TBL] [Abstract][Full Text] [Related]
25. Interventing mitochondrial PD-L1 suppressed IFN-γ-induced cancer stemness in hepatocellular carcinoma by sensitizing sorafenib-induced ferroptosis.
Li T; Huang HY; Qian B; Wang WH; Yuan Q; Zhang HY; He J; Ni KJ; Wang P; Zhao ZY; He JL; Fu SW; Xu L; Lin YC; Lin ZN
Free Radic Biol Med; 2024 Feb; 212():360-374. PubMed ID: 38171407
[TBL] [Abstract][Full Text] [Related]
26. Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma.
Wang Y; Li H; Liang Q; Liu B; Mei X; Ma Y
Tumour Biol; 2015 Mar; 36(3):1561-6. PubMed ID: 25371070
[TBL] [Abstract][Full Text] [Related]
27. Chrysin inhibits hepatocellular carcinoma progression through suppressing programmed death ligand 1 expression.
Rong W; Wan N; Zheng X; Shi G; Jiang C; Pan K; Gao M; Yin Z; Gao ZJ; Zhang J
Phytomedicine; 2022 Jan; 95():153867. PubMed ID: 34923234
[TBL] [Abstract][Full Text] [Related]
28. HBV-specific CD8 T cells present higher TNF-α expression but lower cytotoxicity in hepatocellular carcinoma.
Zhao L; Jin Y; Yang C; Li C
Clin Exp Immunol; 2020 Sep; 201(3):289-296. PubMed ID: 32474905
[TBL] [Abstract][Full Text] [Related]
29. Irradiation Mediates
Cheng CC; Chang YF; Ho AS; Sie ZL; Chang JS; Peng CL; Chang CC
Biomedicines; 2021 Sep; 9(10):. PubMed ID: 34680466
[TBL] [Abstract][Full Text] [Related]
30. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
Huang CY; Tai WT; Hsieh CY; Hsu WM; Lai YJ; Chen LJ; Shiau CW; Chen KF
Cancer Lett; 2014 Jul; 349(2):136-43. PubMed ID: 24735751
[TBL] [Abstract][Full Text] [Related]
31. Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma.
Jiang G; Shi L; Zheng X; Zhang X; Wu K; Liu B; Yan P; Liang X; Yu T; Wang Y; Cai X
Aging (Albany NY); 2020 Jun; 12(12):11466-11484. PubMed ID: 32579541
[TBL] [Abstract][Full Text] [Related]
32. Mesenchymal stromal cells equipped by IFNα empower T cells with potent anti-tumor immunity.
Zhang T; Wang Y; Li Q; Lin L; Xu C; Xue Y; Hu M; Shi Y; Wang Y
Oncogene; 2022 Mar; 41(13):1866-1881. PubMed ID: 35145233
[TBL] [Abstract][Full Text] [Related]
33. Lenvatinib Synergistically Promotes Radiation Therapy in Hepatocellular Carcinoma by Inhibiting Src/STAT3/NF-κB-Mediated Epithelial-Mesenchymal Transition and Metastasis.
Weng YS; Chiang IT; Tsai JJ; Liu YC; Hsu FT
Int J Radiat Oncol Biol Phys; 2023 Mar; 115(3):719-732. PubMed ID: 36245124
[TBL] [Abstract][Full Text] [Related]
34. Sorafenib inhibits interferon production by plasmacytoid dendritic cells in hepatocellular carcinoma.
Zhang X; Xu Y; Zhao G; Liu R; Yu H
BMC Cancer; 2022 Nov; 22(1):1239. PubMed ID: 36451110
[TBL] [Abstract][Full Text] [Related]
35. Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells.
Li D; Sun FF; Wang D; Wang T; Peng JJ; Feng JQ; Li H; Wang C; Zhou DJ; Luo H; Fu ZQ; Zhang T
Oncol Res; 2020 Dec; 28(5):467-481. PubMed ID: 32560747
[TBL] [Abstract][Full Text] [Related]
36. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
[TBL] [Abstract][Full Text] [Related]
37. Decreased IL-6 induces sensitivity of hepatocellular carcinoma cells to sorafenib.
Yang J; Wang J; Luo J
Pathol Res Pract; 2019 Oct; 215(10):152565. PubMed ID: 31387809
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-35 Dampens CD8
Yang L; Shao X; Jia S; Zhang Q; Jin Z
Front Immunol; 2019; 10():1032. PubMed ID: 31134088
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib combined with STAT3 knockdown triggers ER stress-induced HCC apoptosis and cGAS-STING-mediated anti-tumor immunity.
Wang X; Hu R; Song Z; Zhao H; Pan Z; Feng Y; Yu Y; Han Q; Zhang J
Cancer Lett; 2022 Oct; 547():215880. PubMed ID: 35981569
[TBL] [Abstract][Full Text] [Related]
40. Abrine, an IDO1 inhibitor, suppresses the immune escape and enhances the immunotherapy of anti-PD-1 antibody in hepatocellular carcinoma.
Liang X; Gao H; Xiao J; Han S; He J; Yuan R; Yang S; Yao C
Front Immunol; 2023; 14():1185985. PubMed ID: 37334368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
